Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis
Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis
复制标题
DOI：
10.1016/j.amjoto.2010.11.014
复制
发表时间：
2011-11-01
影响因子：
2.5
通讯作者：
Furuya, Nobuhiko
中科院分区：
文献类型：
--
作者：
Shino, Masato;Takahashi, Katsumasa;Furuya, Nobuhiko
我们报告罕见的血管性水肿（也称为Quincke水肿），这是由缬沙坦，一种血管紧张素II受体阻滞剂（ARB）诱导的。arb是为排除血管紧张素转换酶抑制剂的不良反应而开发的一类新型降压药。理论上，arb不会导致血管性水肿的发生，因为它们不会增加血清缓激肽水平，缓激肽是血管性水肿的主要物质。然而，最近发表了一些arb诱导的血管性水肿的报道。在本研究中，我们报告了第4例和亚洲第一例缬沙坦引起的血管性水肿，缬沙坦是arb之一。如果发现血管性水肿，耳鼻喉科医生应警惕开ARB处方并尽快停止ARB治疗。(C) 2011爱思唯尔公司版权所有。
We report the rare case of angioedema (also known as Quincke edema), which was induced by valsartan, an angiotensin II receptor blocker (ARB). ARBs are a new class of antihypertensive agent that is developed to exclude the adverse effects of angiotensin-converting enzyme inhibitors. In theory, ARBs do not contribute to the occurrence of angioedema because they do not increase the serum level of bradykinin, the responsible substance for angioedema. However, some reports of ARB-induced angioedema have recently been published. In this study, we present the forth case and the first Asian case of angioedema due to valsartan, which is one of the ARBs. Otolaryngologist should be wary of the prescribing ARB and discontinue ARBs treatment soon, if angioedema is recognized. (C) 2011 Elsevier Inc. All rights reserved.